Navigation Links
NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
Date:8/27/2007

HUBBARD, Ohio, Aug. 27 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX) is pleased to announce that Chris R. Novak, Esq. has joined the company as Director of Intellectual Property. In addition, we wish to announce that major advances have been made in the rapid detection of Anthrax utilizing the NanoLogix BioNanoChannel(TM) Device.

Mr. Novak has over seven years' experience as an intellectual property counsel in a wide range of high tech industries including the position of Corporate Intellectual Property Counsel of IDT (Integrated Device Technology, Inc.), a NASDAQ 100 semiconductor company with sales of over $800 million a year. Mr. Novak has a Bachelor of Science in Mechanical Engineering and a Juris Doctorate, both awarded by Marquette University. He also holds a Master of Science Degree in Electrical Engineering from Cal Poly State University. Mr. Novak is licensed for the practice of law in California, Colorado, and Wisconsin and the United States Patent and Trademark Office (USPTO) and is preparing for admission to the Ohio Bar. In addition to his experience as a patent attorney, Mr. Novak worked as an engineer for high-tech companies for ten years.

"Mr. Novak will represent NanoLogix as our dedicated intellectual property counsel and manage the expansion and protection of our technologies through patents and other methods. NanoLogix's key asset value is its impressive intellectual property portfolio," said Vice President of Strategic Partnering, Dana Allen. "We are pleased to welcome Chris to the Company in this newly- created role."

"I believe the revolutionary and practical ideas being developed at NanoLogix will have a major impact on the biotechnology and energy fields," said Director of IP Chris Novak, Esq. "We plan to protect these ideas to the fullest extent, and turn these ideas into marketplace realities that will sharply increase revenues."

In another significant development, Nanologix has been working on a request from the United States Department of Defense to explore the potential of rapid determination of Anthrax spore viability, utilizing NanoLogix's BioNanoChannel(TM) (BNC) technology. There appears to be an opportunity to determine the viability and persistence of Anthrax spores much faster than current methods due to the unique rapid culturing aspects of the BNC technology. "Superb progress has been made in our research efforts simulating Anthrax spore growth through the use of non-hazardous spores. This research has the potential to immediately translate to the ability to conduct rapid Anthrax viability testing," said CEO Bret Barnhizer. "We have been impressed with the Department of Defense's dedication to finding the best solution for the security of our country in the event of a biological attack. We look forward to making a major contribution in this area by providing a method by which the government is able to determine the effectiveness of their decontamination efforts in hours rather than days."

About NanoLogix, Inc.

NanoLogix is an industry innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has developed and owns or has rights to 31 patents related to various medical technologies, 5 of which also have hydrogen-generation aspects. In the past year the Company has filed an additional 28 patent applications for discoveries related to hydrogen bioreactors, medical testing, and innovative medical treatments potentially related to leukemia and sepsis. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food. NanoLogix-developed patents are used to design and market diagnostic test kits for use in early detection of the bacteria present in infectious and noninfectious human diseases such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic fibrosis. The company also owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. BioNanoChannel is a Trademark of NanoLogix, Inc. For more information on the Company, visit http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail: Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... 1, 2016 asking the Federal Drug Administration (FDA) to consider OA as a ... OARSI is concerned about the growing population of OA patients, many of whom ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical ... it has acquired the assets of Theorem Clinical Research - Clinical Supplies ... clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016 According to the new market research ... Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and ... the market is expected to grow from USD 10.74 Billion in 2015 ... between 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):